Berry Corbett T, Frazee Caitlin S, Herman Patrick J, Chen Sisi, Chen Anna, Kuo Yvonne, Ellebrecht Christoph T
Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Semin Immunopathol. 2025 Jan 16;47(1):7. doi: 10.1007/s00281-024-01034-5.
The management of autoimmune diseases is currently limited by therapies that largely suppress the immune system, often resulting in partial and temporary remissions. Cellular immunotherapies offer a targeted approach by redirecting immune cells to correct the underlying autoimmunity. This review explores the latest advances in cellular immunotherapies for autoimmune diseases, focusing on various strategies, such as the use of chimeric antigen receptor (CAR) T cells, chimeric auto-antibody receptor (CAAR) T cells, regulatory T cells (Tregs), and tolerogenic dendritic cells (TolDCs). We review recent preclinical studies and results from clinical trials that demonstrate the potential for these therapies to either deplete autoreactive cells or promote immune tolerance through broad or selective targeting of immune cell populations. Key challenges such as ensuring specificity, preventing off-target effects, and improving the longevity of therapeutic effects are discussed. The evolving landscape of cellular immunotherapies holds promise for more durable treatment responses and increased specificity for autoimmune disease treatment.
目前，自身免疫性疾病的治疗受到很大程度上抑制免疫系统的疗法的限制，常常导致部分和暂时的缓解。细胞免疫疗法通过重定向免疫细胞来纠正潜在的自身免疫性，提供了一种靶向方法。本综述探讨了自身免疫性疾病细胞免疫疗法的最新进展，重点关注各种策略，如嵌合抗原受体（CAR）T细胞、嵌合自身抗体受体（CAAR）T细胞、调节性T细胞（Tregs）和耐受性树突状细胞（TolDCs）的使用。我们回顾了最近的临床前研究和临床试验结果，这些研究和结果证明了这些疗法通过广泛或选择性靶向免疫细胞群体来消耗自身反应性细胞或促进免疫耐受的潜力。讨论了确保特异性、防止脱靶效应和提高治疗效果持久性等关键挑战。细胞免疫疗法不断发展的前景有望实现更持久的治疗反应，并提高自身免疫性疾病治疗的特异性。
